ReviewJournal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research2014
How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms.
Review in Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 77 citations in OpenAlex.
- Comparative transcriptome profiling of the lumbosacral dorsal root ganglia reveals sexually dimorphic gene expression in a murine model of coronavirus-induced neurodegeneration.American journal of clinical and experimental urology · 2025Article
- The dichotomic role of cytokines in aging.Biogerontology · 2024Review
- Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.Neurology and therapy · 2024Review
- Expression profiling of cerebrospinal fluid identifies dysregulated antiviral mechanisms in multiple sclerosis.Brain : a journal of neurology · 2024Article
- Article
- A stimulus-contingent positive feedback loop enables IFN-β dose-dependent activation of pro-inflammatory genes.Molecular systems biology · 2023Article
- Type I interferons augment regulatory T cell polarization in concert with ancillary cytokine signals.Frontiers in transplantation · 2023Article
- Article
- Multiplex Analysis of Serum Cytokine Profiles in Systemic Lupus Erythematosus and Multiple Sclerosis.International journal of molecular sciences · 2022Article
- Review
- TLR3-driven IFN-β antagonizes STAT5-activating cytokines and suppresses innate type 2 response in the lung.The Journal of allergy and clinical immunology · 2022Article
- Differential serum interferon-β levels in autoimmune thyroid diseases.Archives of medical science : AMS · 2022Article
- Contribution of Dysregulated B-Cells and IgE Antibody Responses to Multiple Sclerosis.Frontiers in immunology · 2022Review
- Influence of Type I Interferons in Gammaherpesvirus-68 and Its Influence on EAE Enhancement.Frontiers in immunology · 2022Article
- Beta interferons as immunotherapy in multiple sclerosis: a new outlook on a classic drug during the COVID-19 pandemic.QJM : monthly journal of the Association of Physicians · 2021Article
- Interferon b drives intestinal regeneration after radiation.Science advances · 2021Article
- Investigating the shared genetic architecture between multiple sclerosis and inflammatory bowel diseases.Nature communications · 2021Article
- Association study of promoter polymorphisms of interferon alpha and beta receptor subunit 1 (IFNAR1) gene and therapeutic response to interferon-beta in patients with multiple sclerosis.Molecular biology reports · 2021Article
- Type 1 interferon mediates chronic stress-induced neuroinflammation and behavioral deficits via complement component 3-dependent pathway.Molecular psychiatry · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Type I interferons (IFNs) are important in innate and adaptive immunity. They are used to treat virus infections, cancer, and multiple sclerosis (MS). There are 5 type I IFN families in humans-IFN-α with 13 subtypes, plus IFN-β, ɛ, κ, and ω. Because their receptor binding affinities vary, these IFNs have different gene induction profiles and quite variable therapeutic effects. IFN-α subtypes may each be specific for certain viruses, but can be neurotoxic. IFN-β induces IFN-α, plus has additional direct effects on target cells. IFN-β was the first therapy approved that could change the course of MS. It has broader specificity than IFN-α, enhances cognition in MS, and may be neuroprotective and can potentially enhance fertility in women. Priming the IFN signaling system with an injection of IFN-β can enhance subnormal type I IFN signals in MS. Many other commonly used drugs and vitamins may potentiate clinical benefits of IFN-β.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.